From yesterday’s Wall Street Journal:
Pfizer Inc. struck a deal with Indian generic drug maker Ranbaxy Laboratories Ltd. to keep a cheaper version of the blockbuster anti-cholesterol drug Lipitor off the US market until November of 2011.
The deal gives Pfizer an extra 20 months of Lipitor revenue at about $1.083 BILLION PER MONTH.
So Pfizer gets to soak US customers and rake in a measly TWENTY BILLION.